首页> 外文期刊>Bioconjugate Chemistry >Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM197 Carriers
【24h】

Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM197 Carriers

机译:海洛因半抗原结合疫苗的功效而非抗体滴度或亲和力与破伤风类毒素而非CRM197携带者的半抗原密度增加相关

获取原文
获取原文并翻译 | 示例
           

摘要

Vaccines against drugs of abuse have induced antibodies in animals that blocked the biological effects of the drug by sequestering the drug in the blood and preventing it from crossing the blood-brain barrier. Drugs of abuse are too small to induce antibodies and, therefore, require conjugation of drug hapten analogs to a carrier protein. The efficacy of these conjugate vaccines depends on several factors including hapten design, coupling strategy, hapten density, carrier protein selection, and vaccine adjuvant. Previously, we have shown that 1 (MorHap), a heroin/morphine hapten, conjugated to tetanus toxoid (TT) and mixed with liposomes containing monophosphoryl lipid A [L(MPLA)] as adjuvant, partially blocked the antinociceptive effects of heroin in mice. Herein, we extended those findings, demonstrating greatly improved vaccine induced antinociceptive effects up to 3% mean maximal potential effect (%MPE). This was obtained by evaluating the effects of vaccine efficacy of hapten 1 vaccine conjugates with varying hapten densities using two different commonly used carrier proteins, TT and cross-reactive material 197 (CRM197). Immunization of mice with these conjugates mixed with L(MPLA) induced very high anti-1 IgG peak levels of 400-1500 mu g/mL that bound to both heroin and its metabolites, 6-acetylmorphine and morphine. Except for the lowest hapten density for each carrier, the antibody titers and affinity were independent of hapten density. The TT carrier based vaccines induced long-lived inhibition of heroin-induced antinociception that correlated with increasing hapten density. The best formulation contained TT with the highest hapten density of >= 30 haptens/TT molecule and induced %MPE of approximately 3% after heroin challenge. In contrast, the best formulation using CRM197 was with intermediate 1 densities (10-15 haptens/CRM197 molecule), but the % MPE was approximately 13%. In addition, the chemical synthesis of 1, the optimization of the conjugation method, and the methods for the accurate quantification of hapten density are described.
机译:针对滥用药物的疫苗已在动物体内诱导产生抗体,该抗体通过将药物隔离在血液中并防止其穿过血脑屏障来阻止药物的生物学作用。滥用药物太小而无法诱导抗体,因此需要将药物半抗原类似物与载体蛋白结合。这些结合疫苗的功效取决于几个因素,包括半抗原设计,偶联策略,半抗原密度,载体蛋白选择和疫苗佐剂。以前,我们已经证明1(MorHap),一种海洛因/吗啡半抗原,与破伤风类毒素(TT)结合,并与含有单磷酰脂质A [L(MPLA)]作为佐剂的脂质体混合,部分阻断了海洛因对小鼠的镇痛作用。在本文中,我们扩展了这些发现,证明疫苗诱导的抗伤害感受作用大大改善,平均最大潜在作用(%MPE)高达3%。这是通过使用两种不同的常用载体蛋白TT和交叉反应物质197(CRM197)评估半抗原密度不同的半抗原1疫苗偶联物的疫苗功效的影响而获得的。将这些结合物与L(MPLA)混合后对小鼠进行免疫,可诱导400-1500μg / mL的非常高的抗1 IgG峰水平,该峰与海洛因及其代谢产物6-乙酰吗啡和吗啡结合。除了每种载体的最低半抗原密度外,抗体效价和亲和力与半抗原密度无关。基于TT载体的疫苗可长期抑制海洛因诱导的抗伤害感受,这与半抗原密度增加相关。最好的制剂包含具有最高半抗原密度> = 30半抗原/ TT分子的TT,并在海洛因攻击后诱导%MPE约为3%。相反,使用CRM197的最佳配方是中间密度为1(10-15个半抗原/ CRM197分子),但MPE的百分比约为13%。此外,还介绍了1的化学合成,偶联方法的优化以及半抗原密度的准确定量方法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号